Page 15 - Sanket Koul

Novo sticks to oral semaglutide amid rising demand for injectables

Novo Nordisk will strengthen its oral semaglutide portfolio led by Rybelsus while cutting Wegovy injection prices by up to 37% to improve accessibility and expand its market in India

India tops global TB burden in 2024 despite lower incidence: WHO report

India made strong gains in TB reduction, cutting incidence by 21% since 2015, but still accounted for 25% of global cases in 2024, according to the WHO's Global TB Report 2025

Centre reviews initiatives to strengthen nursing education, governance

The Union Health Ministry held consultations to strengthen nursing education and governance, focusing on reforms, skill enhancement and equitable workforce distribution across India

Centre directs states to set up chest clinics amid pollution surge

The Centre has asked all states and UTs to open chest clinics under the National Programme on Climate Change and Human Health to tackle pollution-related illnesses during peak smog months

Hill station homes see 8% demand rise on better connectivity, lifestyle

Buyer and investor interest in India's hill property markets has grown 8.2% YoY in Q3 2025, led by improved connectivity, lifestyle upgrades, and flexible work options, according to Magicbricks

GRAP III norms vital but could delay projects, say realty developers

Developers say adhering to Graded Response Action Plan Phase III is crucial but argue construction is not a major pollution source and blanket bans disrupt timelines and affect workers' livelihoods

Servier India launches subsidised biomarker tests for rare cancers

Servier India has tied up with MedGenome and Reliance-backed Strand Life Sciences to offer low-cost IDH1 and IDH2 biomarker testing for rare cancers like AML and CCA across India

Emcure Q2 PAT up 25%, domestic and international biz drive 13% revenue rise

The company's revenue from operations rose to Rs 2,269.8 crore, a 13.4 per cent increase from Rs 2,001.9 crore in Q2FY25

Sale of immovable property outside scope of service tax: Supreme Court

The revenue department had contested a 2019 order of the Customs, Excise and Service Tax Appellate Tribunal (CESTAT), which had quashed a tax demand exceeding Rs 10 crore

Novo Nordisk cuts weight-loss drug Wegovy prices by up to 37% in India

Move comes in a bid to gain more space in India's anti-obesity market dominated by Mounjaro

Novo Nordisk, Emcure Pharmaceuticals tie up to expand Wegovy's girth

2.4 mg injectable Poviztra to mark next phase of weight-loss rollout

Pharma units likely to face action for Schedule M violations: Experts

The one-year grace period for MSME drug manufacturers to comply with revised Schedule M norms has ended, with the CDSCO instructing state regulators to initiate inspections & action against violators

Knowledge Realty Trust leases 1.8 mn sq ft in H1FY26, GCCs dominate leasing

The real estate investment trust (Reit), backed by Sattva Group and Blackstone, also achieved annual rental escalations on over 90 per cent of leases signed during the H1 period

Over 65% owners paid part of property deal in cash: LocalCircles Survey

'Root cause' of such transactions is regulatory bottlenecks and low circle rates, says LocalCircles

Mounjaro India's bestselling drug in October with ₹100 crore sales

Weight-loss drug rakes in ₹333 cr in cumulative sales since launch in March this year, leaving rival Wegovy behind

Signature Global reports ₹48.8 cr net loss in Q2FY26 amid 56% revenue fall

The developer also saw a 56 per cent year-on-year (Y-o-Y) drop in revenue from operations for Q2FY26 to Rs 338.49 crore, down from Rs 749.28 crore in Q2FY25

Torrent Pharma Q2 profit rises 16% to ₹591 crore on strong global sales

Torrent Pharmaceuticals posted a 16% rise in Q2FY26 profit to Rs 591 crore, with double-digit growth across India, the US, and Brazil driving revenue higher.

India's housing markets see sales slowdown in Q3 2025: Housing.com

Residential sales across India's top eight housing markets stayed flat in Q3 2025 as rising land prices, construction costs, and inflation continued to weigh on affordability

Rebound in US biopharma funding may boost orders, says Piramal Pharma

The drugmaker's revenue fell 9% in Q2FY26 on below-par CDMO performance; company says it faced inconsistent funding in H1FY26

India's housing market to see 5-10% annual price rise, says report

A CII-Colliers report projects housing demand to hit 500,000 units annually by 2030 and 1 million by 2047, driven by urbanisation, income growth, and policy reforms